The Pathophysiology of Heart Failure with Preserved Ejection Fraction and Its Therapeutic Implications;Fisiopatologia da insuficiência cardíaca com FE preservada e suas implica̧ões terapêuticas

Revista Portuguesa de Cardiologia

Volumn 28, Issue 1, 2009, Pages 63-82

  Fontes Carvalho, Ricardo ^a,b   Leite Moreira, Adelino ^a,c  

^a University of Porto   (Portugal)

^b Cento Hospitalar de Vila Nova de Gaia   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Diastole; Heart failure; Pathophysiology; Preserved ejection fraction; Treatment

Indexed keywords

ALAGEBRIUM; ALDOSTERONE ANTAGONIST; ALT 177; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; IVABRADINE; NEBIVOLOL; NITRATE; PERINDOPRIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SPIRONOLACTONE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CAUSAL ATTRIBUTION; CHRONOTROPISM; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC DYSFUNCTION; DIURETIC THERAPY; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEART MUSCLE RELAXATION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM; SYNDROME;

HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 63149106905     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Zille MR. Heart failure with preserved ejection fraction: is this DHF? J Am Coll Cardiol, 2003. 41: 1519-22.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med, 2006 355: 251-9.
3. Paulas W, Tschope C, Sanderson J, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J, 2007. 28: 2539-2550.
4. Yancy CW, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients dmitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol, 2006. 47(1): 76-84.
5. Bhatia RS, Tu TV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med, 2006. 355(3): 260-9.
6. Chen HH, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail, 2002. 8: 279-87.
7. Fonarow GC, Stough WG, Abraham WT. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol, 2007. 50 (8): 768-77.
8. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation, 2002. 105: 1387-93.
9. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med, 2004. 19:1953-1959.
10. Borlaug BA, Kass DA. Ventricular-Vascular Interaction in Heart Failure. Heart Failure Clin, 2008 4: 23-36.
11. ll. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction: Implications for Systolic and Diastolic Reserve Limitations. Circulation, 2003(107): 714-720.
12. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation, 2006. 114: 2138-2147.
13. Leite-Moreira A. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart, 2006. 92: 712-718.
14. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med, 2001. 344: 17-22.
15. Zile MR, Brutsaert DL. New Concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation, 2002. 105: 1503-1508.
16. Aroesty JM, McKay RG, Heller GV, et al. Simultaneous assessment of left ventricular systolic and diastolic dysfunction during pacing-induced ischemia. Circulation, 1985. 71: 889-900.
17. Lester SJ, Tajik AJ, Nishimura RA, Oh JK. Unlocking the Mysteries of Diastolic Function. J Am Coll Cardiol, 2008. 51(7): 679-89.
18. Lam CS, Roger VL., Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation, 2007. 115: 1982-90.
19. Maurer MS, King DL, El-Khoury Rumbarger L, et al. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail, 2005. 11: 177-187.
20. Maurer MS, Burkhoff D, Fried LP, et al. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol, 2007. 49: 972-981.
21. Wang J, Khoury DS, Yue Y, Torre-Amione G, Nagueh SF. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J, 2008. 29:1283-1289.
22. Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet, 2007. 369: 2079-2087.
23. W K Yip, M Wang, T Wang, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart, 2008. 94: 573-580.
24. Paulus W. Beneficial effects of nitric oxide on cardiac diastolic function: 'the flip side of the coin'. Heart Fail Rev, 2000. 5: 337-44.
25. Hunt S.A., Abraham W.T, Marshall H, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 2005. 112: 154-235.
26. Aronow W, Ahn C, Kronzon I. Effect of Propranolol Versus No Propranolol on Total Mortality Plus Nonfatal Myocardial Infarction in Older Patients with Prior Myocardial Infarction, Congestive Heart Failure, and Left Ventricular Ejection Fractio ?40% Treated With Diuretics Plus Angiotensin-Converting Enzyme Inhibitors. Am J Cardiol, 1997. 80(2): 207-209.
27. Dobre D, van Veldhuisen DJ, Dejongste MJ, Lucas C, Cleuren G, Sanderman R, Ranchor AV, Haaijer-Ruskamp FM. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction: clinical implications and survival. Eur J Heart Fail, 2007. 9: 280-6.
28. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 2005. 26: 215-225.
29. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol, 1990. 66: 981-986.
30. Hung MJ, Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract, 2002. 56: 57-62.
31. Mulder P, Barbier S, Chagraoui A, et al. Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradinec Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure. Circulation, 2004. 109: 1674-1679.
32. Brilla CG, Funck RC, Rupp H. Lisinopril mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation, 2000. 102: 1388-93.
33. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation, 2002. 105: 2512-2517.
34. Tsang TS, Barnes ME, Abhayaratna WP, et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol, 2006. 97: 916-20.
35. Schmieder RE, Kjeldsen SE, Julius S, Mclnnes GT, Zanchetti A, Hua TA; VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J. Hypertens. 2008. 26(3): 403-11.
36. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular systohc dysfunction or heart failure: a combined analysis of three trials. Lancet, 2006. 368: 581-588.
37. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan
38. in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHABM-Preserved Trial. Lancet, 2003. 362: 777-781.
39. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study (FASTRACK). Eur Heart J, 2006. 27: 2338-2345.
40. Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M. Prognostic Impact of Angiotensin-Converting Enzyme Inhibitor Therapy in Diastohc Heart Failure. Am J Cardiol, 2008. 101(5): 639-44.
41. Weber KT. Aldosterone in congestive heart failure. N Engl J Med, 2001. 345: 1689-1697.
42. Mottram PM, Haluska B, Leano R et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastohc heart failure. Circulation, 2004.110: 558.
43. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastohc heart failure: the ancillary digitalis investigation group trial. Circulation, 2006. 114: 397403.
44. Massie BM, Abdalla I. Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog Cardiovasc Dis, 1998. 40: 357-369.
45. Zile, M. Treating Diastohc Heart Failure With Statins: That" Chance for Pleiotropic Benefits. Circulation, 2005. 112: 300-303.
46. Fukuta H, Sane DC, Bracks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastohc heart failure: a preliminary report. Circulation, 2005. 112: 357-363.
47. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, 2008 (in press).
48. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 2007. 357: p. 2248-2261.
49. Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastohc heart failure. J Card Fail, 2005. 11: p. 191.
50. Semigran, M. Type 5 Phosphodiesterase Inhibition: The Focus Shifts to the Heart. Circulation, 2005. 112: p. 2589-2591.
51. Goldsmith SR. Type 5 Phosphodiesterase Inhibition in Heart Failure: The Next Step. J Am Coll Cardiol, 2007. 50: p. 214547.